Drug intelligence / Profile preview

RioCard-001

Development stage: Unknown
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

RioCard-001 is a reported investigational **exosome-based regenerative therapy** being developed for **acute myocardial infarction**. A commercial drug-intelligence source identifies it as an exosome product attributed to Rion and reports a highest development stage of Phase 1; however, independently verifiable public details of its molecular composition, manufacturing process, route of administration, specific biological targets, and pharmacologic mechanism were not located. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/b2bf716838a847e0ab2ed0ea86966624))

Beyond the preview

Go deeper on RioCard-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RioCard-001.

Explore the full profile